ANDA 203927, held by Pharmobedient. Acyclovir Sodium.
As of Nov 14, 2026, ANDA 203927 (Acyclovir Sodium), held by Pharmobedient, was first approved by FDA on Mar 29, 2017, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 29, 2017 | Original application | Approved | None posted |
| Acyclovir SodiumEQ 500MG BASE/VIAL · injectable;injection | Acyclovir Sodium | Discontinued |
| Acyclovir SodiumEQ 1GM BASE/VIAL · injectable;injection | Acyclovir Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
